Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging.
about
Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathyCardiac Magnetic Resonance and Computed Tomography in Hypertrophic Cardiomyopathy: an Update.Reproducibility of Gadolinium Enhancement Patterns and Wall Thickness in Hypertrophic Cardiomyopathy.Relation of late gadolinium enhancement in cardiac magnetic resonance on the diastolic volume recovery of left ventricle with hypertrophic cardiomyopathy.Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability.Dual manganese-enhanced and delayed gadolinium-enhanced MRI detects myocardial border zone injury in a pig ischemia-reperfusion model.Left Atrial Mechanical Function and Global Strain in Hypertrophic Cardiomyopathy.Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?Impact of nonischemic scar features on local ventricular electrograms and scar-related ventricular tachycardia circuits in patients with nonischemic cardiomyopathy.Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.Current Role And Future Prospects Of Magnetic Resonance Imaging In The Field Of Atrial Fibrillation Ablation.Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy.Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathyMyocardial fibrosis evaluated by Look-Locker and late gadolinium enhancement magnetic resonance imaging in apical hypertrophic cardiomyopathy: association with ventricular tachyarrhythmia and risk factors.Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.Assessment of myocardial fibrosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: comparison with MR and coronary angiography.Myocardial scar identification based on analysis of Look-Locker and 3D late gadolinium enhanced MRI.Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.Disease-specific differences of left ventricular rotational mechanics between cardiac amyloidosis and hypertrophic cardiomyopathy.Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.MRI classification of asymmetric septal hypertrophic cardiomyopathy and its relation to the presence of risk factors
P2860
Q26999424-8074F078-6210-4AD9-A5D0-EBAC1E561CE0Q30371882-22DCEBE5-14C6-4546-AC21-2A553622C292Q30376835-50CC4429-0273-4283-B053-4CA13F07BA5FQ33995246-72B04074-1CF5-43C9-ACA3-16D5A993547FQ34014152-3523674D-25F1-4AC2-B848-ACC4CD5612BCQ34428462-E0B665F8-12D3-4448-8169-DE07E22B105AQ35228078-F7D131F8-00B9-436E-8C45-14203EA05A29Q36059907-D8CFFCBC-27D6-4A5B-AA11-5A72B10A08C8Q36571308-B475632A-9A59-4F68-ADDF-2E77228BC47AQ37448010-25FEF4C2-C97C-4544-AA64-64FD0AED4827Q37631139-22933AF8-D9AA-4746-803F-0E6BA7542DB8Q38948582-FF8E51AD-3CE1-41FA-A79B-AC1A04E3DB6CQ41566334-BCECB775-190E-4B3F-A48C-33E9B420801CQ42278868-B19DC818-0B9F-47DD-B0CB-E42DCD0F88D6Q43506080-6CD9E389-D616-440B-A266-D47F5A7F3792Q43535198-5EE05155-AA54-45C6-9422-75DFC90EC47DQ43931913-6971F368-A09D-42D2-917B-CC42B0358322Q45754126-E6C4AB8E-42B1-4010-A2DC-26222C820C86Q46009548-E4E7816D-3B2D-4BA6-BEE0-F21A1DE37460Q47801890-6A3E50A2-0B5A-4851-9698-0FADD78087C6Q48659291-26F95D77-A3C6-47BD-8D01-A4E6CCA30C1CQ50585961-FDB13F9B-B636-4CCB-A55C-DB022E3FF94BQ50614147-FCEFC015-D51F-4179-849C-5D8A8781E859Q52891701-93CFB35B-8325-4FDC-9E89-681A597B7F14Q58376931-061F33ED-E8BF-4D26-960D-7435910D9C1E
P2860
Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@en
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@nl
type
label
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@en
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@nl
prefLabel
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@en
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@nl
P2093
P356
P1433
P1476
Hypertrophic cardiomyopathy: q ...... ced cardiovascular MR imaging.
@en
P2093
Barry J Maron
C Michael Gibson
Caitlin J Harrigan
Dana C Peters
Evan Appelbaum
Martin S Maron
P304
P356
10.1148/RADIOL.10090526
P407
P577
2010-11-02T00:00:00Z